Logo image of RDHL

REDHILL BIOPHARMA LTD-SP ADR (RDHL) Stock Fundamental Analysis

NASDAQ:RDHL - Nasdaq - US7574683014 - ADR - Currency: USD

4.76  -0.14 (-2.86%)

After market: 4.76 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RDHL. RDHL was compared to 194 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of RDHL while its profitability can be described as average. RDHL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

RDHL had positive earnings in the past year.
RDHL had a negative operating cash flow in the past year.
In the past 5 years RDHL reported 4 times negative net income.
RDHL had a negative operating cash flow in each of the past 5 years.
RDHL Yearly Net Income VS EBIT VS OCF VS FCFRDHL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of RDHL (108.59%) is better than 100.00% of its industry peers.
RDHL's Return On Equity of 39206.56% is amongst the best of the industry. RDHL outperforms 100.00% of its industry peers.
RDHL has a Return On Invested Capital of 1261.60%. This is amongst the best in the industry. RDHL outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 108.59%
ROE 39206.56%
ROIC 1261.6%
ROA(3y)1.58%
ROA(5y)-18.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RDHL Yearly ROA, ROE, ROICRDHL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

With an excellent Profit Margin value of 366.25%, RDHL belongs to the best of the industry, outperforming 99.46% of the companies in the same industry.
With an excellent Operating Margin value of 193.45%, RDHL belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
RDHL has a Gross Margin of 47.03%. This is comparable to the rest of the industry: RDHL outperforms 59.46% of its industry peers.
In the last couple of years the Gross Margin of RDHL has declined.
Industry RankSector Rank
OM 193.45%
PM (TTM) 366.25%
GM 47.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.3%
GM growth 5Y-6.56%
RDHL Yearly Profit, Operating, Gross MarginsRDHL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), RDHL is creating value.
The number of shares outstanding for RDHL has been increased compared to 1 year ago.
RDHL has more shares outstanding than it did 5 years ago.
RDHL has a better debt/assets ratio than last year.
RDHL Yearly Shares OutstandingRDHL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
RDHL Yearly Total Debt VS Total AssetsRDHL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -24.01, we must say that RDHL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -24.01, RDHL is not doing good in the industry: 88.11% of the companies in the same industry are doing better.
RDHL has a Debt/Equity ratio of 3.11. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 3.11, RDHL is doing worse than 82.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.11
Debt/FCF N/A
Altman-Z -24.01
ROIC/WACC678.28
WACC1.86%
RDHL Yearly LT Debt VS Equity VS FCFRDHL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 0.74 indicates that RDHL may have some problems paying its short term obligations.
RDHL has a worse Current ratio (0.74) than 94.59% of its industry peers.
A Quick Ratio of 0.56 indicates that RDHL may have some problems paying its short term obligations.
RDHL has a Quick ratio of 0.56. This is amonst the worse of the industry: RDHL underperforms 92.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.56
RDHL Yearly Current Assets VS Current LiabilitesRDHL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 292.28% over the past year.
The Revenue for RDHL has decreased by -89.43% in the past year. This is quite bad
RDHL shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.82% yearly.
EPS 1Y (TTM)292.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-89.43%
Revenue growth 3Y-53.36%
Revenue growth 5Y-4.82%
Sales Q2Q%42.89%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 63.11% on average over the next years. This is a very strong growth
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year131.11%
Revenue Next 2Y105.48%
Revenue Next 3Y77.82%
Revenue Next 5Y63.11%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RDHL Yearly Revenue VS EstimatesRDHL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
RDHL Yearly EPS VS EstimatesRDHL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500 -1K -1.5K -2K -2.5K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.00, the valuation of RDHL can be described as very cheap.
Based on the Price/Earnings ratio, RDHL is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.63, RDHL is valued rather cheaply.
Industry RankSector Rank
PE 0
Fwd PE N/A
RDHL Price Earnings VS Forward Price EarningsRDHL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.05
RDHL Per share dataRDHL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 500 1K 1.5K 2K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RDHL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REDHILL BIOPHARMA LTD-SP ADR

NASDAQ:RDHL (2/21/2025, 8:00:01 PM)

After market: 4.76 0 (0%)

4.76

-0.14 (-2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-16 2024-09-16
Earnings (Next)N/A N/A
Inst Owners6.77%
Inst Owner Change178.79%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.10M
Analysts82.86
Price Target19380 (407042.86%)
Short Float %166.52%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0
Fwd PE N/A
P/S 0.93
P/FCF N/A
P/OCF N/A
P/B 99.92
P/tB N/A
EV/EBITDA -0.05
EPS(TTM)2119.18
EY44520.59%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-18.92
FCFYN/A
OCF(TTM)-18.92
OCFYN/A
SpS5.1
BVpS0.05
TBVpS-4.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 108.59%
ROE 39206.56%
ROCE 1596.97%
ROIC 1261.6%
ROICexc N/A
ROICexgc N/A
OM 193.45%
PM (TTM) 366.25%
GM 47.03%
FCFM N/A
ROA(3y)1.58%
ROA(5y)-18.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.3%
GM growth 5Y-6.56%
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 3.11
Debt/FCF N/A
Debt/EBITDA 0.01
Cap/Depr 0.24%
Cap/Sales 0.03%
Interest Coverage 168.43
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.56
Altman-Z -24.01
F-Score4
WACC1.86%
ROIC/WACC678.28
Cap/Depr(3y)1.22%
Cap/Depr(5y)126.92%
Cap/Sales(3y)0.21%
Cap/Sales(5y)17.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)292.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-89.43%
Revenue growth 3Y-53.36%
Revenue growth 5Y-4.82%
Sales Q2Q%42.89%
Revenue Next Year131.11%
Revenue Next 2Y105.48%
Revenue Next 3Y77.82%
Revenue Next 5Y63.11%
EBIT growth 1Y129.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.66%
OCF growth 3YN/A
OCF growth 5YN/A